All News

Orca-T is a “big advance” that must be studied further among patients with acute leukemias and myelodysplastic syndromes.

Amer Zeidan, MBBS, MD, discusses how mutation status and physical fitness factor into frontline AML regimen selection.

A prospective subsidized breast biopsy and navigation program at a Kenyan referral hospital achieved same-day CNB in 100% of 104 patients with invasive breast carcinoma, revealing high rates of aggressive subtypes and median 8-month prediagnostic delays, with 16.35% mortality during follow-up.

Intraoperative surgeon-performed PECs block during mastectomy resulted in only 16.6% of patients requiring postoperative opioids, supporting this technique as a fast and effective method of regional analgesia.

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

The FDA has issued a third CRL for the combination based on manufacturing site deficiencies associated with the new drug application.

Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML.

Findings from the phase 3 KEYNOTE-B15/EV-304 trial support the approval of pembrolizumab-based treatment in this bladder cancer population.

Miguel A. Materin, MD, discussed insights on multidisciplinary care, intra-arterial chemotherapy, and the evolving landscape of uveal melanoma treatments.

Data from studies including the IRAKLIA trial support the approval of subcutaneous isatuximab plus standard of care in multiple myeloma.

In 278 patients with a positive family history of breast cancer followed for a median 96 months, local recurrence, regional recurrence, and CBC risk were comparable to general population rates by SIR analysis, with recurrence risk driven more by biological subtype than family history.

In 52 patients with multifocal upper inner quadrant breast cancer, a modified Würinger central pedicle mastopexy enabled large-volume oncoplastic resections with 80.8% patient satisfaction and significant BREAST-Q quality-of-life improvement, with no major infectious complications.

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.

Jonathan Lee, MD, MSc, and Chinmay Jani, MD, have a candid conversation about what medical training actually feels like.

Ateganosine plus cemiplimab showed an acceptable safety profile among patients with third-line NSCLC in the phase 2 THIO-101 trial.

Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care.

Sivraj Muralikrishnan, MD, analyzed HARMONi-6 safety findings for ivonescimab in NSCLC, addressing VEGF-related toxicities and global generalizability.

Advanced oncoplastic breast surgery using multiple pedicles for complex defect reconstruction demonstrated oncologic safety and acceptable complication rates in selected patients undergoing breast-conserving surgery.

Targeted axillary dissection with sentinel lymph node biopsy successfully retrieved all preoperatively identified positive nodes in node-positive breast cancer patients treated with neoadjuvant chemotherapy, with no axillary recurrences observed.

Education and reinforcement may improve luspatercept dose titration and persistence in community practice.

The European Medicines Agency has begun a phased review of daraxonrasib for pancreatic cancer as the FDA nears completion of a rolling new drug application submission.

Miguel A. Materin, MD, discussed his new leadership role at Northwell Cancer Institute, and why a multidisciplinary approach is critical to managing ocular malignancies.

A phase 1 study evaluating the safety, tolerability, and feasibility of intravesical UGN-501 is expected to begin in the fourth quarter of 2026.

Data from a phase 2 trial show the potential of inotuzumab ozogamicin to deepen remissions in patients with B-cell acute lymphoblastic leukemia.

Sivraj Muralikrishnan, MD, highlighted top head and neck cancer data from ASCO, including the KEYNOTE-689 trial and the novel mRNA degrader REM-422.

In 21 patients with metaplastic breast cancer receiving neoadjuvant chemotherapy, 48% achieved pCR—higher than prior estimates—with all pCR patients alive and disease-free at follow-up, suggesting modern regimens including pembrolizumab may improve outcomes in this chemoresistant subtype.

In 391 Venezuelan breast cancer patients receiving NACT, normal BMI was associated with higher pCR (31.6% vs 15.8% overweight and 14.7% obese) and significantly better OS at 120 months, supporting BMI as a relevant prognostic and predictive factor.

Catch up on key data in colorectal, pancreatic, and hepatocellular cancers presented at the ESMO Gastrointestinal Cancers Congress 2026.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed sequencing options like luspatercept after ESA failure in RS-negative lower-risk MDS.

The European Commission approved epcoritamab/R2 for adult patients with relapsed/refractory follicular lymphoma based on the phase 3 EPCORE FL-1 data.